Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

as seen in the chart below. The stock is currently trading above its 50-day moving average but below its 200-day moving average. Several factors in the past three months caused Novo Nordisk's ...

Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Novo Nordisk is rated Zacks Rank #4 (Sell). The chart below shows the ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...